It is estimated approximately 50% and 34% of patients with diabetes will be affected by diabetic neuropathy (DN) and DFU over the course of their lifetime, respectively
We want to make sure the signals are clear
Phase 3 monotherapy available Feature Expected GI burden Cagrilintide + Retatrutide Very high CagriSema (Cag + Sema) High Retatrutide Alone High Feature Dysesthesia risk Cagrilintide + Retatrutide Yes (retatrutide component) CagriSema (Cag + Sema) No Retatrutide Alone Yes Feature Injections per week Cagrilintide + Retatrutide 2 (separate) or 1 (pre-blend) CagriSema (Cag + Sema) 1 or 2 Retatrutide Alone 1 Feature Regulatory status Cagrilintide + Retatrutide Neither approved
(8) A Steiger, J Guldner, U Hemmeter, B Rothe, et al (1992) Effects of growth hormone-releasing hormone and somatostatin on sleep EEG and nocturnal hormone secretion in male controls Neuroendocrinology, 1992 Oct, Volume 56 (Issue 4), Pages 566-73
Directional integration and pathway enrichment analysis for multi-omics data